
|Articles|April 10, 2008
Abatacept approved by FDA for use in children
Bristol-Myers Squibb granted approval for arthritis biologic Orencia.
Advertisement
Children ages six years and older with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) may now get some relief from using abatacept (
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Updated COVID-19 Vaccines Effectively Protect Against Symptomatic Infection
2
Patient Interest Remains High for Pharmacist-Led Reproductive Care
3
Oral GLP-1 Aleniglipron Produces Up to 12.1% Weight Loss
4
Expertise, Protocols Make Pharmacists Essential Prescribers
5
























